Findings

What do systematic reviews say?

427 questions · 437 findings · 29 reviews · Schizophrenia

Sort:Best matchNewest Highest certainty Download CSV

No studies found 77 · 17.6%GRADE not reported 61 · 14%Very low 130 · 29.7%Low 103 · 23.6%Moderate 54 · 12.4%High 12 · 2.7%

Perazine vs OTHER ANTIPSYCHOTICS

Mental state · patients with schizophrenia

1 finding from 1 review

Perazine for schizophrenia 2014 · Cochrane Headline outcomes only
no estimate extracted
1 study · 40 participants
Low

Acupuncture vs STANDARD DOSE ANTIPSYCHOTICS

Global state: not improved ‐ short‐term GAF · patients with schizophrenia

It is very uncertain whether ACUPUNCTURE changes global state: Not improved (talk, behaviour and expression still… compared with STANDARD DOSE ANTIPSYCHOTICS (very low certainty).

1 finding from 1 review

Acupuncture for schizophrenia 2014 · Cochrane Headline outcomes only
RR 0.33 [0.19, 0.59]
2 studies · 240 participants
Very low

Acupuncture vs STANDARD DOSE ANTIPSYCHOTICS

Mental state: psychopathology Total endpoint data, BPRS (higher score = worse, scale from: 0‐126) · patients with schizophrenia

1 finding from 1 review

Acupuncture for schizophrenia 2014 · Cochrane Headline outcomes only
no estimate extracted
1 study · 32 participants
Very low

Acupuncture vs STANDARD DOSE ANTIPSYCHOTICS

Behaviour: Leaving the study early (short‐term) · patients with schizophrenia

1 finding from 1 review

Acupuncture for schizophrenia 2014 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 421 participants
Low

Acupuncture vs STANDARD DOSE ANTIPSYCHOTICS

Service outcomes: Hospitalisation · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Acupuncture for schizophrenia 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Acupuncture vs STANDARD DOSE ANTIPSYCHOTICS

Adverse effects: any observed extrapyramidal symptoms ‐ short term (up to 6 months) · patients with schizophrenia

ACUPUNCTURE may leads to lower adverse effects: Extrapyramidal symptoms (short‐term) compared with STANDARD DOSE ANTIPSYCHOTICS (low certainty).

1 finding from 1 review

Acupuncture for schizophrenia 2014 · Cochrane Headline outcomes only
RR 0.05 [0, 0.83]
1 study · 21 participants
Low

Acupuncture vs STANDARD DOSE ANTIPSYCHOTICS

Quality of life: No clinically important change in quality of life · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Acupuncture for schizophrenia 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Acupuncture vs STANDARD DOSE ANTIPSYCHOTICS

Economic outcomes: Cost of care · patients with schizophrenia

The review found no eligible studies for this question.

1 finding from 1 review

Acupuncture for schizophrenia 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

FLUPENTHIXOL vs LOW‐POTENCY ANTIPSYCHOTIC DRUGS

Response to treatment · patients with schizophrenia

1 finding from 1 review

Flupenthixol versus low‐potency first‐generation antipsychotic drugs for schizophrenia 2014 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

FLUPENTHIXOL vs LOW‐POTENCY ANTIPSYCHOTIC DRUGS

Acceptability of treatment ‐ leaving the study early · patients with schizophrenia

1 finding from 1 review

Flupenthixol versus low‐potency first‐generation antipsychotic drugs for schizophrenia 2014 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

FLUPENTHIXOL vs LOW‐POTENCY ANTIPSYCHOTIC DRUGS

Risk for at least one adverse event per patient · patients with schizophrenia

1 finding from 1 review

Flupenthixol versus low‐potency first‐generation antipsychotic drugs for schizophrenia 2014 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

FLUPENTHIXOL vs LOW‐POTENCY ANTIPSYCHOTIC DRUGS

Adverse effects ‐ movement disorders ‐ At least one movement disorder · patients with schizophrenia

1 finding from 1 review

Flupenthixol versus low‐potency first‐generation antipsychotic drugs for schizophrenia 2014 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

FLUPENTHIXOL vs LOW‐POTENCY ANTIPSYCHOTIC DRUGS

Adverse effects: 1. Sedation · patients with schizophrenia

1 finding from 1 review

Flupenthixol versus low‐potency first‐generation antipsychotic drugs for schizophrenia 2014 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

FLUPENTHIXOL vs LOW‐POTENCY ANTIPSYCHOTIC DRUGS

Adverse effects ‐ death · patients with schizophrenia

1 finding from 1 review

Flupenthixol versus low‐potency first‐generation antipsychotic drugs for schizophrenia 2014 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

FLUPENTHIXOL vs LOW‐POTENCY ANTIPSYCHOTIC DRUGS

Quality of life · patients with schizophrenia

1 finding from 1 review

Flupenthixol versus low‐potency first‐generation antipsychotic drugs for schizophrenia 2014 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

QUETIAPINE vs Typical antipsychotics

Global state: No clinically significant response (as defined by the original studies) · patients with schizophrenia

Quetiapine showed no clear difference in global state No clinical significant response as defined by the… compared with typical antipsychotics (moderate certainty).

1 finding from 1 review

Quetiapine versus typical antipsychotic medications for schizophrenia 2013 · Cochrane Headline outcomes only
RR 0.96 [0.75, 1.23]
16 studies · 1607 participants
Moderate

QUETIAPINE vs Typical antipsychotics

Leaving the study early · patients with schizophrenia

Quetiapine showed no clear difference in leaving the study early due to any reason compared with typical antipsychotics (moderate certainty).

1 finding from 1 review

Quetiapine versus typical antipsychotic medications for schizophrenia 2013 · Cochrane Headline outcomes only
RR 0.91 [0.81, 1.01]
23 studies · 3576 participants
Moderate

QUETIAPINE vs Typical antipsychotics

Mental state: 2. Positive symptoms ‐ average endpoint score PANSS positive subscore · patients with schizophrenia

1 finding from 1 review

Quetiapine versus typical antipsychotic medications for schizophrenia 2013 · Cochrane Headline outcomes only
no estimate extracted
22 studies · 1934 participants
Moderate

QUETIAPINE vs Typical antipsychotics

Mental state: 3. Negative symptoms ‐ average endpoint score PANSS negative subscore · patients with schizophrenia

1 finding from 1 review

Quetiapine versus typical antipsychotic medications for schizophrenia 2013 · Cochrane Headline outcomes only
no estimate extracted
22 studies · 1934 participants
Moderate

QUETIAPINE vs Typical antipsychotics

Cognitive function · patients with schizophrenia

1 finding from 1 review

Quetiapine versus typical antipsychotic medications for schizophrenia 2013 · Cochrane Headline outcomes only
no estimate extracted
3 studies · 142 participants
Very low